The post XRP Recovers to $1.38 as Market Focus Shifts to XRP Australia 2026 appeared on BitcoinEthereumNews.com. XRP was trading at $1.38 on Feb. 25, which is aThe post XRP Recovers to $1.38 as Market Focus Shifts to XRP Australia 2026 appeared on BitcoinEthereumNews.com. XRP was trading at $1.38 on Feb. 25, which is a

XRP Recovers to $1.38 as Market Focus Shifts to XRP Australia 2026

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

XRP was trading at $1.38 on Feb. 25, which is a bit of a comeback from the early February lows near $1.11. This is happening as the market shifts its focus to XRP Australia 2026. This regional industry conference is bringing adoption, regulation and enterprise deployment back into the near-term narrative, making sure that the price rebound and event-driven focus happen at the same time and not in isolation.

On the daily chart by TradingView, XRP/USD went up 2.13% to $1.3786 after briefly hitting above $1.40. This keeps the price stuck in the $1.34 to $1.48 range it has been in since the capitulation leg earlier this month.

XRP/USD Daily Chart, Source: TradingView

The daily RSI has recovered to the 38-39 range from oversold conditions, but it is still below the neutral 50 threshold. This shows that the buyers are in control, but this control is not fully established yet. On shorter time frames, the price is stable around $1.38, which shows consistent demand, but it is not as strong as the buying the market usually sees when a trend is starting.

Ripple’s CTO Emeritus Shuts Down ‘Nonsensical’ Centralization Accusations

Crypto Market Review: Shiba Inu Is Completely Baseless, XRP’s Stabilization Price Level Nears $1.20, Bitcoin Dives Below $62,720

XRP Australia 2026 as catalyst

XRP Australia 2026 is now entering trader models as a significant catalyst window. While conferences do not necessarily change the protocol mechanics, they commonly happen at the same time as:

  • Partnership disclosures and corridor expansions.
  • Institutional integrations, in this case within the Asia-Pacific region.
  • Regulatory updates impacting Ripple-linked infrastructure.

You Might Also Like

The anticipation of the Sydney conference affects short-term capital allocation before solid announcements are made. XRP is still stuck in a range between $1.48 and $1.60. It will have to break out of that range to go above $1.60. So, the recovery to $1.38 is a sign of strength after a sharp drop, not a sure sign that things are changing.

Source: https://u.today/xrp-recovers-to-138-as-market-focus-shifts-to-xrp-australia-2026

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3663
$1.3663$1.3663
+0.72%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09